Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23957
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorKarabina, S. A.en
dc.contributor.authorTambaki, A. P.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorMiltiadous, G.en
dc.contributor.authorGoudevenos, J. A.en
dc.contributor.authorCariolou, M. A.en
dc.contributor.authorChapman, M. J.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:36:53Z-
dc.date.available2015-11-24T19:36:53Z-
dc.identifier.issn0022-2275-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23957-
dc.rightsDefault Licence-
dc.subject1-Alkyl-2-acetylglycerophosphocholine Esteraseen
dc.subjectAdulten
dc.subjectApolipoproteins/*metabolismen
dc.subjectCholesterol, HDL/*metabolismen
dc.subjectCholesterol, LDL/*metabolismen
dc.subjectEnzyme Activationen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHyperlipoproteinemia Type II/classification/*enzymology/geneticsen
dc.subjectLipoproteins/blood/classification/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPhospholipases A/*blood/metabolismen
dc.subjectPhospholipases A2en
dc.subjectSeverity of Illness Indexen
dc.titleAltered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11861667-
heal.identifier.secondaryhttp://www.jlr.org/content/43/2/256.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2002-
heal.abstractPlatelet-activating factor-acetylhydrolase (PAF-AH) is a lipoprotein-associated phospholipase A2 capable of hydrolyzing platelet-activating factor (PAF) and oxidatively modified phospholipids. We studied the plasma- and lipoprotein-associated PAF-AH activity in patients with primary hypercholesterolemia. Thirty-eight unrelated patients with heterozygous familial hypercholesterolemia (HeteroFH), five patients with homozygous FH (HomoFH), and 33 patients with primary non-FH hypercholesterolemia (NonFH) participated in the study. In all patient groups the plasma PAF-AH activity was significantly elevated compared with 33 normolipidemic controls, the HomoFH having the highest and the NonFH patients showing the lowest enzyme activity. Gradient ultracentrifugation studies showed that this increase is not only due to the elevation in the plasma LDL but also to the increase in the PAF-AH activity associated with each LDL subfraction, being more profound in the small-dense LDL-5. Unlike LDL, no difference in the HDL-associated PAF-AH activity was observed among all groups. Consequently, an altered distribution of enzyme activity among apolipoprotein B (apoB)- and apolipoprotein A-I (apoA-I)-containing lipoproteins is observed in hypercholesterolemic patients, resulting in a significant decrease in the ratio of the HDL-associated PAF-AH to the total plasma enzyme activity compared with controls. This reduction is proportional to the increase of the plasma LDL-cholesterol (LDL-C) levels and consequently to the severity of the hypercholesterolemia. Thus, the ratio of HDL-associated PAF-AH-total plasma enzyme activity may be useful as a potential marker of atherogenicity in subjects with primary hypercholesterolemia.en
heal.journalNameJournal of Lipid Researchen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Tsimihodimos-2002-Altered distribution.pdf397.89 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons